Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one ...

Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...

Here's how this small medical device company is helping to tackle diabetes and why it might be worth buying in your portfolio. Given there are 1.5 million new cases of diabetes diagnosed every year in ...

FreeStyle Libre is a continuous glucose monitoring (CGM) system. It uses a sensor to read and check a person’s glucose levels. People with diabetes can use FreeStyle Libre to help manage the condition ...

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...

Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated ...

DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...

Diabetes rivals settled patent dispute in 2014 New court complaints filed after agreement expired in March Abbott says DexCom breached settlement agreement, patent license (Reuters) - An Abbott ...